Gestational diabetes & diabetes in pregnancy
Postnatal Cardiometabolic Health After Metformin Use in Gestational Diabetes: A Secondary Analysis of the EMERGE Trial
Authors' conclusion
Early metformin use in GDM did not impact important cardiometabolic parameters in the early postpartum period despite significant benefits in weight gain and insulin use in pregnancy.
Study context
- Population
- Women with gestational diabetes mellitus (GDM) randomized at diagnosis, assessed 12 ± 4 weeks postpartumpregnancies assessed postpartum
- Participants
- 478 pregnancies
- Comparison
- Metformin vs placebo from GDM diagnosis
- Metforminn = 237
- Placebon = 241reference
- Primary endpoint
- Postpartum cardiometabolic risk factors: weight, body mass index (BMI), waist circumference, blood pressure, 75-g OGTT, fasting insulin, C-peptide, lipids
- Follow-up
- 12 ± 4 weeks postpartum
Methodological detailsdouble-blind, placebo-controlled
- Double-blind
- Placebo-controlled
Primary result
As reported in the abstract
Postpartum weight · postpartum visit
P = 0.04
Further findings
| Outcome | Metformin | Placebo | P value |
|---|---|---|---|
| Postpartum BMI · postpartum visitLower with metformin | 29.3 ([ ] 5.6) | 30.5 ([ ] 5.4) | P = 0.018 |
Weight change from randomization to 12 weeks postpartum
- No difference between metformin and placebo
Prediabetes or diabetes · postpartum
- Whole cohort meeting criteria for prediabetes or diabetes
- 29% (n = 139)
- No positive impact with metformin
Insulin resistance, blood pressure, lipids · postpartum
- No differences between groups
Original publication
Postnatal Cardiometabolic Health After Metformin Use in Gestational Diabetes: A Secondary Analysis of the EMERGE Trial. J Clin Endocrinol Metab. Published 26 July 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →